Nxera Pharma Co., Ltd.

TSE:4565 Stock Report

Market Cap: JP¥101.8b

Nxera Pharma Valuation

Is 4565 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4565 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4565 (¥1132) is trading below our estimate of fair value (¥3202.77)

Significantly Below Fair Value: 4565 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4565?

Key metric: As 4565 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4565. This is calculated by dividing 4565's market cap by their current revenue.
What is 4565's PS Ratio?
PS Ratio3.5x
SalesJP¥29.28b
Market CapJP¥101.77b

Price to Sales Ratio vs Peers

How does 4565's PS Ratio compare to its peers?

The above table shows the PS ratio for 4565 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
4559 Zeria Pharmaceutical
1.2x7.5%JP¥98.9b
4553 Towa Pharmaceutical
0.6x5.1%JP¥138.8b
4569 KYORIN Pharmaceutical
0.7x-2.1%JP¥86.1b
4551 Torii Pharmaceutical
2.3x3.9%JP¥133.6b
4565 Nxera Pharma
3.5x9.3%JP¥101.8b

Price-To-Sales vs Peers: 4565 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does 4565's PS Ratio compare vs other companies in the JP Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
4541 Nichi-Iko Pharmaceutical
0.1xn/aUS$185.57m
8095 Astena Holdings
0.4xn/aUS$127.91m
4539 Nippon Chemiphar
0.2xn/aUS$35.21m
No more companies available in this PS range
4565 3.5xIndustry Avg. 1.9xNo. of Companies6PS01.63.24.86.48+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4565 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the JP Pharmaceuticals industry average (1.9x).

Price to Sales Ratio vs Fair Ratio

What is 4565's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4565 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: 4565 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4565 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,132.00
JP¥2,060.00
+82.0%
33.3%JP¥3,900.00JP¥1,300.00n/a10
Nov ’25JP¥1,213.00
JP¥2,070.00
+70.7%
32.8%JP¥3,900.00JP¥1,300.00n/a10
Oct ’25JP¥1,226.00
JP¥2,090.00
+70.5%
30.7%JP¥3,900.00JP¥1,500.00n/a10
Sep ’25JP¥1,400.00
JP¥2,122.22
+51.6%
31.6%JP¥3,900.00JP¥1,500.00n/a9
Aug ’25JP¥1,663.00
JP¥2,122.22
+27.6%
31.6%JP¥3,900.00JP¥1,500.00n/a9
Jul ’25JP¥1,568.00
JP¥2,111.11
+34.6%
31.8%JP¥3,900.00JP¥1,500.00n/a9
Jun ’25JP¥1,452.00
JP¥2,111.11
+45.4%
31.8%JP¥3,900.00JP¥1,500.00n/a9
May ’25JP¥1,494.00
JP¥2,100.00
+40.6%
32.5%JP¥3,900.00JP¥1,500.00n/a9
Apr ’25JP¥1,638.00
JP¥2,112.50
+29.0%
34.2%JP¥3,900.00JP¥1,500.00n/a8
Mar ’25JP¥1,550.00
JP¥2,112.50
+36.3%
33.4%JP¥3,900.00JP¥1,500.00n/a8
Feb ’25JP¥1,422.00
JP¥2,167.50
+52.4%
32.2%JP¥3,900.00JP¥1,540.00n/a8
Jan ’25JP¥1,421.00
JP¥2,242.50
+57.8%
35.0%JP¥4,200.00JP¥1,540.00n/a8
Dec ’24JP¥1,418.00
JP¥2,262.86
+59.6%
37.3%JP¥4,200.00JP¥1,540.00n/a7
Nov ’24JP¥1,398.00
JP¥2,281.25
+63.2%
34.2%JP¥4,200.00JP¥1,550.00JP¥1,213.008
Oct ’24JP¥1,492.00
JP¥2,335.71
+56.5%
35.1%JP¥4,200.00JP¥1,550.00JP¥1,226.007
Sep ’24JP¥1,658.00
JP¥2,335.71
+40.9%
35.1%JP¥4,200.00JP¥1,550.00JP¥1,400.007
Aug ’24JP¥1,846.00
JP¥2,507.14
+35.8%
35.7%JP¥4,200.00JP¥1,550.00JP¥1,663.007
Jul ’24JP¥1,500.00
JP¥2,657.14
+77.1%
47.1%JP¥4,500.00JP¥1,100.00JP¥1,568.007
Jun ’24JP¥3,115.00
JP¥3,500.00
+12.4%
24.3%JP¥4,500.00JP¥1,800.00JP¥1,452.007
May ’24JP¥2,740.00
JP¥3,214.29
+17.3%
26.8%JP¥4,200.00JP¥1,800.00JP¥1,494.007
Apr ’24JP¥2,267.00
JP¥3,166.67
+39.7%
28.8%JP¥4,200.00JP¥1,800.00JP¥1,638.006
Mar ’24JP¥2,148.00
JP¥3,133.33
+45.9%
28.0%JP¥4,200.00JP¥1,800.00JP¥1,550.006
Feb ’24JP¥2,447.00
JP¥3,116.67
+27.4%
28.1%JP¥4,200.00JP¥1,800.00JP¥1,422.006
Jan ’24JP¥2,138.00
JP¥3,116.67
+45.8%
28.1%JP¥4,200.00JP¥1,800.00JP¥1,421.006
Dec ’23JP¥1,881.00
JP¥3,116.67
+65.7%
28.1%JP¥4,200.00JP¥1,800.00JP¥1,418.006
Nov ’23JP¥2,030.00
JP¥2,900.00
+42.9%
34.7%JP¥4,200.00JP¥1,800.00JP¥1,398.006

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Tsumura

JP¥368.9b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,858.00

7D

1.2%

1Y

76.3%

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,094.50

7D

-2.1%

1Y

-10.9%

Daito PharmaceuticalLtd

JP¥32.8b

Manufactures and sells pharmaceutical products worldwide.

4577

JP¥2,147.00

7D

1.8%

1Y

8.8%